CY1112800T1 - Η χρηση υποκαθιστουμενων κυανοπυρρολιδινων για τη θεραπεια της υπερλιπιδαιμιας - Google Patents
Η χρηση υποκαθιστουμενων κυανοπυρρολιδινων για τη θεραπεια της υπερλιπιδαιμιαςInfo
- Publication number
- CY1112800T1 CY1112800T1 CY20091100499T CY091100499T CY1112800T1 CY 1112800 T1 CY1112800 T1 CY 1112800T1 CY 20091100499 T CY20091100499 T CY 20091100499T CY 091100499 T CY091100499 T CY 091100499T CY 1112800 T1 CY1112800 T1 CY 1112800T1
- Authority
- CY
- Cyprus
- Prior art keywords
- hyperlipidemia
- treatment
- substituted
- methods
- cyanopyrrolidines
- Prior art date
Links
- 208000031226 Hyperlipidaemia Diseases 0.000 title abstract 2
- QJRYYOWARFCJQZ-UHFFFAOYSA-N pyrrolidine-1-carbonitrile Chemical class N#CN1CCCC1 QJRYYOWARFCJQZ-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 206010022562 Intermittent claudication Diseases 0.000 abstract 1
- 208000032382 Ischaemic stroke Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 206010028851 Necrosis Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 238000002399 angioplasty Methods 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000021156 intermittent vascular claudication Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000017074 necrotic cell death Effects 0.000 abstract 1
- 230000000291 postprandial effect Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38522002P | 2002-06-03 | 2002-06-03 | |
| EP03737984A EP1513519B1 (en) | 2002-06-03 | 2003-06-02 | The use of substituted cyanopyrrolidines for treating hyperlipidemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1112800T1 true CY1112800T1 (el) | 2016-02-10 |
Family
ID=29712145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20091100499T CY1112800T1 (el) | 2002-06-03 | 2009-05-11 | Η χρηση υποκαθιστουμενων κυανοπυρρολιδινων για τη θεραπεια της υπερλιπιδαιμιας |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20050176806A1 (enExample) |
| EP (1) | EP1513519B1 (enExample) |
| JP (2) | JP2005532338A (enExample) |
| KR (1) | KR20050012771A (enExample) |
| CN (2) | CN100402026C (enExample) |
| AT (1) | ATE422884T1 (enExample) |
| AU (2) | AU2003245903B2 (enExample) |
| BR (1) | BR0311535A (enExample) |
| CA (1) | CA2487297C (enExample) |
| CY (1) | CY1112800T1 (enExample) |
| DE (1) | DE60326232D1 (enExample) |
| DK (1) | DK1513519T3 (enExample) |
| EC (1) | ECSP045469A (enExample) |
| ES (1) | ES2321600T3 (enExample) |
| IL (1) | IL165181A (enExample) |
| MX (1) | MXPA04012149A (enExample) |
| NO (1) | NO333585B1 (enExample) |
| NZ (1) | NZ536832A (enExample) |
| PL (1) | PL210408B1 (enExample) |
| PT (1) | PT1513519E (enExample) |
| RU (1) | RU2362555C2 (enExample) |
| SG (1) | SG154333A1 (enExample) |
| SI (1) | SI1513519T1 (enExample) |
| WO (1) | WO2003101448A1 (enExample) |
| ZA (1) | ZA200409136B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100402026C (zh) * | 2002-06-03 | 2008-07-16 | 诺瓦提斯公司 | 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途 |
| AR041089A1 (es) * | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
| JP5122144B2 (ja) * | 2004-01-20 | 2013-01-16 | ノバルティス アーゲー | 直接圧縮製剤および方法 |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| WO2006083214A1 (en) * | 2005-02-02 | 2006-08-10 | Astrazeneca Ab | Pharmaceutical composition comprising a p2x7 receptor antagonist and a hmg-coa reductase inhibitor |
| MX2007011453A (es) | 2005-04-22 | 2008-02-12 | Alantos Pharmaceuticals Holding Inc | Inhibidores de la dipeptidil peptidasa-iv. |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| WO2008097535A2 (en) * | 2007-02-08 | 2008-08-14 | Merck & Co., Inc. | Method of treating atherosclerosis, dyslipidemias and related conditions |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| JP2013523819A (ja) | 2010-04-06 | 2013-06-17 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置 |
| CN103221410B (zh) | 2010-09-22 | 2017-09-15 | 艾尼纳制药公司 | Gpr119受体调节剂和对与其相关的障碍的治疗 |
| KR101298788B1 (ko) * | 2011-03-15 | 2013-08-22 | 보령제약 주식회사 | 안정성이 개선된 복합제제 |
| US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| EA021236B1 (ru) * | 2012-10-03 | 2015-05-29 | Дафот Энтерпраизес Лимитед | Nα-АЦИЛЬНЫЕ ПРОИЗВОДНЫЕ АМИНОАЦИЛ-2-ЦИАНОПИРРОЛИДИНА - ИНГИБИТОРЫ ПРОЛИЛЭНДОПЕПТИДАЗЫ И ДИПЕПТИДИЛПЕПТИДАЗЫ-IV, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКИМ, ПРОТИВОГИПОКСИЧЕСКИМ, НЕЙРОПРОТЕКТОРНЫМ И УЛУЧШАЮЩИМ КОГНИТИВНЫЕ ФУНКЦИИ ДЕЙСТВИЕМ |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| CN107683135A (zh) | 2015-03-09 | 2018-02-09 | 因特克林医疗有限公司 | 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法 |
| AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
| EA202192328A1 (ru) * | 2019-03-22 | 2022-02-21 | Раш Юниверсити Медикал Сентер | Комбинация назальной доставки генов и пероральной доставки коричной кислоты, олеамида или гемфиброзила для лечения лизосомных болезней накопления |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2572399B1 (fr) * | 1984-10-31 | 1987-01-16 | Panmedica Sa | Nouveaux derives de l'adamantanamine, leurs procedes de preparation et medicaments les contenant |
| TW222626B (enExample) * | 1991-07-22 | 1994-04-21 | Pfizer | |
| DE122010000020I1 (de) * | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| EP1052994A2 (en) * | 1998-02-02 | 2000-11-22 | Trustees Of Tufts College | Use of dipeptidylpetidase inhibitors to regulate glucose metabolism |
| DE19828114A1 (de) * | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
| DE19828113A1 (de) * | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| CN1332726A (zh) * | 1998-11-02 | 2002-01-23 | 卫福有限公司 | 吡咯烷化合物及其药物用途 |
| CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| JP4232332B2 (ja) * | 1999-11-10 | 2009-03-04 | 末藏 岩田 | タンク付電動床磨機用ブラシ台 |
| ATE385421T1 (de) * | 2000-01-21 | 2008-02-15 | Novartis Pharma Gmbh | Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica |
| JP2005507261A (ja) * | 2001-10-31 | 2005-03-17 | ノバルティス アクチエンゲゼルシャフト | Ｔｃｆ１遺伝子における多型に基づく糖尿病および関連状態の治療方法 |
| PE20040291A1 (es) * | 2002-03-22 | 2004-07-02 | Novartis Ag | COMBINACION QUE COMPRENDE UN INHIBIDOR DE HMG-CoA-REDUCTASA Y UN POTENCIADOR DE LA SECRECION DE INSULINA Y/O UN SENSIBILIZANTE DE INSULINA |
| GB0212412D0 (en) * | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
| CN100402026C (zh) * | 2002-06-03 | 2008-07-16 | 诺瓦提斯公司 | 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途 |
| WO2005117861A1 (en) * | 2004-06-04 | 2005-12-15 | Novartis Ag | Use of organic compounds |
| AU2006292377B2 (en) * | 2005-09-20 | 2011-03-03 | Emisphere Technologies, Inc. | Use of a DPP-IV inhibitor to reduce hypoglycemic events |
-
2003
- 2003-06-02 CN CNB038128446A patent/CN100402026C/zh not_active Expired - Fee Related
- 2003-06-02 RU RU2004139029/14A patent/RU2362555C2/ru not_active IP Right Cessation
- 2003-06-02 MX MXPA04012149A patent/MXPA04012149A/es active IP Right Grant
- 2003-06-02 ES ES03737984T patent/ES2321600T3/es not_active Expired - Lifetime
- 2003-06-02 CA CA2487297A patent/CA2487297C/en not_active Expired - Fee Related
- 2003-06-02 DE DE60326232T patent/DE60326232D1/de not_active Expired - Lifetime
- 2003-06-02 BR BR0311535-6A patent/BR0311535A/pt not_active IP Right Cessation
- 2003-06-02 EP EP03737984A patent/EP1513519B1/en not_active Expired - Lifetime
- 2003-06-02 PT PT03737984T patent/PT1513519E/pt unknown
- 2003-06-02 SI SI200331571T patent/SI1513519T1/sl unknown
- 2003-06-02 KR KR10-2004-7019595A patent/KR20050012771A/ko not_active Ceased
- 2003-06-02 AT AT03737984T patent/ATE422884T1/de active
- 2003-06-02 PL PL374016A patent/PL210408B1/pl not_active IP Right Cessation
- 2003-06-02 AU AU2003245903A patent/AU2003245903B2/en not_active Ceased
- 2003-06-02 WO PCT/EP2003/005762 patent/WO2003101448A1/en not_active Ceased
- 2003-06-02 CN CNA2008100965659A patent/CN101273987A/zh active Pending
- 2003-06-02 SG SG200608456-0A patent/SG154333A1/en unknown
- 2003-06-02 JP JP2004508806A patent/JP2005532338A/ja not_active Withdrawn
- 2003-06-02 DK DK03737984T patent/DK1513519T3/da active
- 2003-06-02 NZ NZ536832A patent/NZ536832A/en not_active IP Right Cessation
- 2003-06-02 US US10/516,633 patent/US20050176806A1/en not_active Abandoned
-
2004
- 2004-11-11 ZA ZA2004/09136A patent/ZA200409136B/en unknown
- 2004-11-11 IL IL165181A patent/IL165181A/en not_active IP Right Cessation
- 2004-12-01 EC EC2004005469A patent/ECSP045469A/es unknown
- 2004-12-14 NO NO20045452A patent/NO333585B1/no not_active IP Right Cessation
-
2006
- 2006-11-30 AU AU2006246483A patent/AU2006246483B9/en not_active Ceased
-
2009
- 2009-05-11 CY CY20091100499T patent/CY1112800T1/el unknown
-
2010
- 2010-04-05 JP JP2010087181A patent/JP2010155866A/ja active Pending
-
2011
- 2011-09-26 US US13/245,226 patent/US20120014907A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1513519T3 (da) | Anvendelse af substituerede cyanopyrrolidiner til behandling af hyperlipidæmi | |
| MXPA02012034A (es) | Derivados de tiofeno utiles como agentes anticancerosos. | |
| DE602006007012D1 (de) | Pyridinderivate als dipeptedyl-peptidase-hemmer | |
| HRP20041137B1 (hr) | Indolni, azaindolni i srodni heterocikliäśni 4-alkenil piperidinski amidi | |
| EA200500814A1 (ru) | Производные пирролопиримидина | |
| CY1109925T1 (el) | Η χρηση πυριδυλ αμιδιων ως παρεμποδιστων της αγγειογενεσης | |
| ATE320426T1 (de) | Harnstoffderivate und ihre verwendung | |
| PE20041076A1 (es) | Nuevas pirazolopirimidinas como inhibidores de la quinasa dependientes de ciclina | |
| MY135218A (en) | 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases | |
| AP1564A (en) | Piperazinyl sulfonic acid derivatives, their pharmaceutical compositions and methods of use. | |
| BR0313385A (pt) | Derivados de pirimidina-2,4-diona como inibidores de metaloproteinase da matriz | |
| NO20050573L (no) | 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler | |
| ATE373636T1 (de) | Amidderivate als inhibitoren der enzymatischen aktivität von renin | |
| NO20074173L (no) | Nye 3-fenylpropionsyrederivater og deres anvendelse som PPAR-gamma-reseptorligand | |
| ATE464043T1 (de) | Pharmazeutische zusammensetzung enthaltend l- arginin | |
| TW200716597A (en) | Novel piperidine-substituted indoles | |
| RU2007132179A (ru) | Ингибирующие вич производные 2-(4-цианофениламино)пиримидина | |
| DK1789044T3 (da) | Phenylaminopyridiner og phenylaminopyraziner | |
| MY143862A (en) | Piperidine-substituted indoles-or heteroderivatives thereof | |
| ATE295845T1 (de) | Prucaloprid-n-oxid | |
| ATE432262T1 (de) | Pyrazolphenylderivate als ppar-aktivatoren | |
| ATE408610T1 (de) | Alkyl-und piperidin-substitutierte benzimidazol- derivate | |
| DE60312154D1 (de) | 2-oxo-1,3,4-trihydrochinazolin derivative zur behandlung von zellproliferationskrankheiten | |
| ATE259802T1 (de) | Verbindungen mit antithrombotischer wirkung | |
| DK0706796T3 (da) | Dopamingenoptagelsesinhibitorer til behandling af parkinsonisme |